

Jörg Lippert

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2721943/publications.pdf>

Version: 2024-02-01

12
papers

285
citations

1162367

8
h-index

1199166

12
g-index

12
all docs

12
docs citations

12
times ranked

266
citing authors

#	ARTICLE	IF	CITATIONS
1	Finerenone Dose-Exposure-Response for the Primary Kidney Outcome in FIDELIO-DKD Phase III: Population Pharmacokinetic and Time-to-Event Analysis. <i>Clinical Pharmacokinetics</i> , 2022, 61, 439-450.	1.6	11
2	Finerenone Dose-Exposure-Serum Potassium Response Analysis of FIDELIO-DKD Phase III: The Role of Dosing, Titration, and Inclusion Criteria. <i>Clinical Pharmacokinetics</i> , 2022, 61, 451-462.	1.6	15
3	Dose-Exposure-Response Analysis of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone on UACR and eGFR: An Analysis from FIDELIO-DKD. <i>Clinical Pharmacokinetics</i> , 2022, 61, 1013-1025.	1.6	10
4	Model-informed bridging of rivaroxaban doses for thromboprophylaxis in pediatric patients aged 9% years and older with congenital heart disease. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2022, 11, 1111-1121.	1.3	3
5	A generic framework for the physiologically-based pharmacokinetic platform qualification of PK-Sim and its application to predicting cytochrome P450 3A4-mediated drug-drug interactions. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 633-644.	1.3	15
6	Predictive Performance of Physiology-Based Pharmacokinetic Dose Estimates for Pediatric Trials: Evaluation With 10 Bayer Small-Molecule Compounds in Children. <i>Journal of Clinical Pharmacology</i> , 2021, 61, S70-S82.	1.0	11
7	Population pharmacokinetic analysis of rivaroxaban in children and comparison to prospective physiologically-based pharmacokinetic predictions. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 1195-1207.	1.3	7
8	Population Pharmacokinetic and Exposure-Response Analysis of Finerenone: Insights Based on Phase IIb Data and Simulations to Support Dose Selection for Pivotal Trials in Type 2 Diabetes with Chronic Kidney Disease. <i>Clinical Pharmacokinetics</i> , 2020, 59, 359-370.	1.6	22
9	Open Systems Pharmacology Community: An Open Access, Open Source, Open Science Approach to Modeling and Simulation in Pharmaceutical Sciences. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2019, 8, 878-882.	1.3	58
10	Predictive Pediatric Modeling and Simulation Using Ontogeny Information. <i>Journal of Clinical Pharmacology</i> , 2019, 59, S95-S103.	1.0	23
11	Pharmacokinetics of rivaroxaban in children using physiologically based and population pharmacokinetic modelling: an EINSTEIN-Jr phase I study. <i>Thrombosis Journal</i> , 2018, 16, 32.	0.9	40
12	Development of a Paediatric Population-Based Model of the Pharmacokinetics of Rivaroxaban. <i>Clinical Pharmacokinetics</i> , 2014, 53, 89-102.	1.6	70